INTERNATIONAL PATENT: CROSSBOW THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM FILES APPLICATION FOR "TCR MIMETIC T CELL ENGAGING ANTIBODIES TARGETING HUMAN LEUKOCYTE ANTIGEN CATHEPSIN G PEPTIDE COMPLEX, CD3 AND CD28"

GENEVA, May 13 -- CROSSBOW THERAPEUTICS, INC. (1030 Massachusetts Ave.Suite 210Cambridge, MA 02138), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (210 W 7th StAustin, TX 78701) filed a patent application (PCT/US2025/054006) for "TCR MIMETIC T CELL ENGAGING ANTIBODIES TARGETING HUMAN LEUKOCYTE ANTIGEN CATHEPSIN G PEPTIDE COMPLEX, CD3, AND CD28" on Nov 04, 2025. With publication no. WO/2026/097085, the details related to the patent application was published on May 07, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MAK, Nga, Sze Amanda (1030 Massachusetts Ave.Suite 210Cambridge, MA 02138),...